BAFF blockade in experimental autoimmune encephalomyelitis reduces inflammation in the meninges and synaptic and neuronal loss in adjacent brain regions

K Gupta, Ajay Kesharwani, Steven Rua, Saumitra Sen Singh, Catherine Siu, Larissa Jank, Matthew D. Smith, Peter A. Calabresi, Pavan BhargavaJournal of Neuroinflammation 2023 · DOI

TL;DR

This study investigates the role of BAFF, a key B-cell survival factor, in experimental autoimmune encephalomyelitis (EAE), a model for Multiple Sclerosis (MS). By blocking BAFF in EAE mice, researchers significantly reduced inflammatory cell infiltration in the meninges and, crucially, preserved neurons and synapses in adjacent brain regions, suggesting BAFF blockade as a promising therapeutic avenue for MS.

What Problem Does This Paper Address?

Multiple Sclerosis (MS) is traditionally understood as a white matter disease driven by inflammation and demyelination. However, recent research highlights the significant contribution of gray matter pathology and inflammation in the meninges (the membranes surrounding the brain and spinal cord) to MS-related disability. Leptomeningeal inflammation, characterized by the presence of immune cells like B cells, T cells, and macrophages, is increasingly recognized as a driver of gray matter damage. BAFF (B cell-activating factor) is a cytokine known to promote B cell survival and maturation, and also influences T cells. Given its role in immune cell activity, BAFF presents a potential therapeutic target for reducing this detrimental meningeal inflammation and subsequent neurodegeneration in MS. This paper aims to explore whether blocking BAFF can ameliorate meningeal inflammation and protect neuronal and synaptic integrity in an animal model of MS.

Methods

The researchers utilized a relapsing-remitting EAE (rr-EAE) mouse model, induced by immunizing SJL/J mice with a myelin protein peptide. To assess the impact of BAFF blockade, mice were treated with either an anti-BAFF antibody (10F4) or a control IgG antibody.

Key techniques employed include:

  • Ultra-high field (11.7 T) MRI: Used to non-invasively track and quantify meningeal inflammation (visualized as contrast enhancement) over time in live animals. This allowed for the measurement of leptomeningeal enhancement (LME) volume.
  • Immunohistochemistry: Performed on post-mortem brain tissue to analyze the cellular composition of meningeal infiltrates (identifying B cells, T cells, and myeloid cells) and to assess neuronal and synaptic density in the hippocampus and cortex. Specific markers like B220, CD3, Mac2, NeuN, and PSD95 were used.
  • Statistical Analysis: A range of statistical methods, including mixed-effects analysis and Welch's t-tests/Mann-Whitney U-tests, were used to compare treatment groups and assess the significance of observed changes.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from the EAE mouse model.

Key Insights and Ideas

  • Meningeal Inflammation is a Key Target: The study reinforces the idea that targeting meningeal inflammation, not just central nervous system lesions, is crucial for treating MS.
  • BAFF as a Central Player: The findings strongly implicate BAFF in driving the inflammatory infiltrate within the meninges, highlighting its importance in the pathogenesis of EAE.
  • Beyond Inflammation Reduction: The most striking insight is that reducing meningeal inflammation via BAFF blockade directly translates to neuroprotection, preserving neurons and synapses in adjacent brain areas. This suggests a direct link between meningeal health and neuronal integrity.
  • Cellular Composition Matters: The reduction in specific immune cell types (B cells, T cells, myeloid cells) in the meninges upon BAFF blockade provides a mechanistic understanding of how the treatment exerts its effects.
  • MRI as a Powerful Tool: The use of high-field MRI to track meningeal inflammation in vivo demonstrates its utility in monitoring disease progression and treatment response in preclinical models.

Key Results

  • Reduced Inflammatory Infiltrates: Treatment with the anti-BAFF antibody 10F4 significantly reduced the proportion of B cells (B220+), T cells (CD3+), and myeloid cells (Mac2+) within the meningeal infiltrates compared to the IgG control group.
  • Preservation of Neurons and Synapses: Anti-BAFF treated mice showed significantly higher synaptic density (PSD95) and neuronal density (NeuN) in the hippocampus (CA1, CA3, and DG regions) and in the cortex adjacent to meningeal infiltrates, compared to control mice.
  • No Significant Impact on Clinical Scores: Interestingly, anti-BAFF treatment did not significantly alter the overall clinical behavioral scores of the EAE mice during the observed treatment period. This suggests that while the treatment impacts underlying pathology, its effect on gross motor function in this specific model and timeframe was not statistically significant.
  • Trend in MRI Enhancement: While not statistically significant, MRI data showed a trend towards less leptomeningeal enhancement (LME) volume in the anti-BAFF treated group compared to the IgG control group over time, suggesting a potential for reduced inflammation.

Limitations and Future Work

The authors acknowledge several limitations:

  • Mechanism of B-cell Reduction: It's unclear whether the observed reduction in B cells is due to decreased survival or reduced recruitment, as BAFF plays a role in both.
  • Neuronal Stress vs. Loss: The study measured NeuN expression, which indicates neuronal nuclei, but couldn't definitively distinguish between neuronal stress and actual neuronal loss.
  • Treatment Duration and Timing: The 4-week treatment period might have been insufficient to observe significant effects on clinical scores. Longer treatment durations or earlier intervention might yield different results.
  • Hindbrain Imaging: The MRI protocol was optimized for the forebrain, limiting the ability to comment on potential BAFF effects in the hindbrain.
  • Potential for Additional Dosing: The authors suggest that longer treatment or additional dosing of the BAFF antibody might be beneficial.

Future work could focus on:

  • Investigating the precise mechanisms by which BAFF blockade reduces B cell numbers.
  • Exploring the long-term effects of BAFF blockade on clinical outcomes and disease progression.
  • Expanding imaging to include the hindbrain to assess regional differences in treatment effects.
  • Investigating the potential of BAFF blockade in combination with other therapies.
  • Further exploring the role of BAFF in neuroprotection beyond its anti-inflammatory effects, potentially through interactions with neuronal pathways.

Summary updated

Abstract

Multiple sclerosis (MS) has traditionally been viewed as a chronic inflammatory disease affecting the white matter of the central nervous system. However, over the past two decades, increasing evidence has highlighted the role of gray matter pathology in MS-related disability. Numerous studies have linked the presence of leptomeningeal inflammation to a more severe disease course, underscoring its potential importance as a driver of gray matter pathology in MS. The major components of leptomeningeal inflammation include T cells, B cells, macrophages, follicular dendritic cells, and plasma cells. Since BAFF [B cell-activating factor of the tumor necrosis factor (TNF) family] promotes B cell survival and maturation and is a co-stimulator of T cells, we used anti-BAFF antibody 10F4 as a BAFF antagonist to study its effect on meningeal inflammation and adjacent brain regions in a relapsing-remitting PLP-EAE (rr-EAE) model of multiple sclerosis in SJL/J mice. rr-EAE mice were treated either with anti-BAFF antibody 10F4 or with IgG control antibody. We performed ultra-high field (11.7 T) MRI to identify areas of meningeal inflammation and track them over time in both treatment groups. We also performed histopathological analysis in brain sections of these mice to study the effects of the BAFF antagonist on leptomeningeal inflammation, and hippocampal and cortical neurons and synapses. We observed that BAFF antagonist treatment reduced B cells, T cells, and myeloid cells in regions of meningeal inflammation. Additionally, we noted that BAFF treatment protected against EAE-induced synaptic and neuronal loss in the adjacent cortex and in the CA1, CA3, and dentate gyrus regions of the hippocampus likely due to its effects on meningeal inflammation.
BibTeX
@article{gupta2023baff,
  author = {K Gupta and Ajay Kesharwani and Steven Rua and Saumitra Sen Singh and Catherine Siu and Larissa Jank and Matthew D. Smith and Peter A. Calabresi and Pavan Bhargava},
  title = {{BAFF blockade in experimental autoimmune encephalomyelitis reduces inflammation in the meninges and synaptic and neuronal loss in adjacent brain regions}},
  journal = {Journal of Neuroinflammation},
  year = {2023},
  doi = {10.1186/s12974-023-02922-7},
}
Figure